(Z)-N′-hydroxy-4-(4-(trifluoromethyl)phenoxy)benzimidamide | 1136832-69-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-N′-hydroxy-4-(4-(trifluoromethyl)phenoxy)benzimidamide
• 英文别名: N'-hydroxy-4-[4-(trifluoromethyl)phenoxy]benzenecarboximidamide
• CAS: 1136832-69-3
• 化学式: C₁₄H₁₁F₃N₂O₂
• 分子量: 296.249
• InChiKey: GDIDTPDXATYYCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (Z)-N′-hydroxy-4-(4-(trifluoromethyl)phenoxy)benzimidamide 在 盐酸 、 铁粉 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 6.5h， 生成 4-(3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)aniline
  参考文献：
  名称：

  Discovery of a New Class of Non-β-lactam Inhibitors of Penicillin-Binding Proteins with Gram-Positive Antibacterial Activity

  摘要：

  Infections caused by hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA) are a serious global public-health concern, as MRSA has become broadly resistant to many classes of antibiotics. We disclose herein the discovery of a new class of non-beta-lactam antibiotics, the oxadiazoles, which inhibit penicillin-binding protein 2a (PBP2a) of MRSA. The oxadiazoles show bactericidal activity against vancomycin-and linezolid-resistant MRSA and other Gram-positive bacterial strains, in vivo efficacy in a mouse model of infection, and have 100% oral bioavailability.

  DOI：

  10.1021/ja500053x
• 作为产物：
  描述：

  对三氟甲基苯酚 在 copper(l) iodide 、 羟胺 、 N,N-二甲基甘氨酸盐酸盐 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 141.0h， 生成 (Z)-N′-hydroxy-4-(4-(trifluoromethyl)phenoxy)benzimidamide
  参考文献：
  名称：

  Discovery of a New Class of Non-β-lactam Inhibitors of Penicillin-Binding Proteins with Gram-Positive Antibacterial Activity

  摘要：

  Infections caused by hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA) are a serious global public-health concern, as MRSA has become broadly resistant to many classes of antibiotics. We disclose herein the discovery of a new class of non-beta-lactam antibiotics, the oxadiazoles, which inhibit penicillin-binding protein 2a (PBP2a) of MRSA. The oxadiazoles show bactericidal activity against vancomycin-and linezolid-resistant MRSA and other Gram-positive bacterial strains, in vivo efficacy in a mouse model of infection, and have 100% oral bioavailability.

  DOI：

  10.1021/ja500053x

文献信息

• ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME
  申请人：Mobashery Shahriar

  公开号：US20100261673A1

  公开（公告）日：2010-10-14

  Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.

  本发明的实施例提供了针对青霉素结合蛋白或其他重要细胞靶标的新型抗菌剂。本文描述的化合物用于抑制细菌的生长（繁殖等）的方法也得到提供。各种实施例对革兰氏阳性细菌表现出活性，如某些肠球菌和金黄色葡萄球菌菌株。
• [EN] ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2009041972A1

  公开（公告）日：2009-04-02

  Embodiments of the present invention provide novel antibactehals that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.

  本发明实施例提供了针对青霉素结合蛋白或其他重要细胞靶点的新型抗菌剂。本文描述的化合物用于抑制细菌的生长（繁殖等）的方法也提供了。各种实施例对革兰氏阳性细菌表现出活性，例如某些肠球菌和金黄色葡萄球菌菌株。
• Antibacterial compounds and methods of using same
  申请人：Mobashery Shahriar

  公开号：US09045442B2

  公开（公告）日：2015-06-02

  Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.

  本发明的实施例提供了新型抗菌剂，其靶向青霉素结合蛋白或其他重要的细胞靶点。本文所述化合物抑制细菌的生长（繁殖等）的方法也被提供。各种实施例对革兰氏阳性菌表现出活性，例如某些肠球菌和金黄色葡萄球菌菌株。
• Non-beta lactam antibiotics
  申请人：University of Notre Dame du Lac

  公开号：US10662164B2

  公开（公告）日：2020-05-26

  The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.

  本发明提供了一种新发现的噁二唑类抗生素。噁二唑类抗生素会损害细胞壁的生物合成，对革兰氏阳性细菌，如金黄色葡萄球菌，包括耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素金黄色葡萄球菌和耐利奈唑胺金黄色葡萄球菌具有活性。例如，5-(1H-吲哚-5-基)-3-(4-(4-(三氟甲基)苯氧基)苯基)-1,2,4-恶二唑（抗生素 75b）在 MRSA 感染的小鼠模型中疗效显著，半衰期长，分布容积大，清除率低。抗生素 75b 具有杀菌和口服生物利用度高的特点。这一类抗生素可用作治疗革兰氏阳性菌（如 MRSA）感染的药物。
• Structure–Activity Relationship for the Oxadiazole Class of Antibiotics
  作者：Edward Spink、Derong Ding、Zhihong Peng、Marc A. Boudreau、Erika Leemans、Elena Lastochkin、Wei Song、Katerina Lichtenwalter、Peter I. O’Daniel、Sebastian A. Testero、Hualiang Pi、Valerie A. Schroeder、William R. Wolter、Nuno T. Antunes、Mark A. Suckow、Sergei Vakulenko、Mayland Chang、Shahriar Mobashery

  DOI：10.1021/jm501661f

  日期：2015.2.12

  The structure-activity relationship (SAR) for the newly discovered oxadiazole class of antibiotics is described with evaluation of 120 derivatives of the lead structure. This class of antibiotics was discovered by in silico docking and scoring against the crystal structure of a penicillin-binding protein. They impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. 5-(1H-Indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. This antibiotic is bactericidal and is orally bioavailable in mice. This class of antibiotics holds great promise in recourse against infections by MRSA.